A recent study also demonstrates that siglec-9 expressed by CD8+ tumor infiltrating lymphocytes (TILs) in non-small cell lung cancer (NSCLC) patients was associated with reduced survival. Here, CD8A is linked to non-small cell lung carcinoma.